Ubs Group Ag Vaxxinity, Inc. Call Options Transaction History
Ubs Group Ag
- $400 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VAXX
# of Institutions
7Shares Held
287KCall Options Held
0Put Options Held
0-
Pathstone Family Office, LLC Englewood, NJ154KShares$00.0% of portfolio
-
Xtx Topco LTD London, X067.1KShares$00.0% of portfolio
-
ETF Managers Group, LLC Summit, NJ43.8KShares$00.0% of portfolio
-
Glenmede Trust CO Na Philadelphia, PA19.2KShares$00.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ2.39KShares$00.0% of portfolio
About Vaxxinity, Inc.
- Ticker VAXX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 112,150,000
- Description
- Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...